Prestige Consumer Healthcare Inc. PBH

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to "we," "us," "our," the "Company" or "Prestige" refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., "2026") refers to our fiscal year ended March 31 of that year.

We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage. Our ultimate success is dependent on several factors, including our ability to:

Last close 47.80 2026-10-23
Market cap $2.26B 2026-06-30 share count
52-week range 42.62 - 71.07

Valuation FY2025 figures against the last close

P/S2.1x
P/E12.2x
P/FCF9.2x
EV/EBITDA9.4x
Dividend yield—
Diluted EPS3.91

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Rest of world
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 850.4M (78.1%) 78% United States Rest of world, FY2025: 238.3M (21.9%) 22% Rest of world FY2024 United States, FY2024: 897.5M (78.9%) 79% Rest of world, FY2024: 240.2M (21.1%) 21% FY2023 United States, FY2023: 886.5M (78.8%) 79% Rest of world, FY2023: 238.9M (21.2%) 21%
Region FY2025FY2024FY2023
United States $850.4M $897.5M $886.5M
Rest of world $238.3M $240.2M $238.9M

As the company reported it, from the “Business Segments (Revenue by Geographic Area) (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.09B$1.14B$1.13B$1.13B$1.09B$943.4M$963.0M$975.8M$1.04B$882.1M
Cost of revenue $493.1M$503.3M$500.9M$502.4M$466.2M$395.9M$410.8M$420.2M$464.7M$381.8M
Gross profit $595.6M$634.5M$624.4M$625.3M$620.6M$547.5M$552.2M$555.6M$576.5M$500.3M
SG&A $116.4M$108.2M$106.2M$107.4M$107.5M$83.1M$89.1M$89.8M$85.4M$89.1M
Total operating expenses $286.2M$297.7M$282.0M$647.7M$290.7M$250.1M$261.1M$488.1M$361.0M$294.6M
Operating income $309.4M$336.8M$342.4M-$22.4M$329.9M$297.4M$291.2M$67.5M$215.5M$205.6M
Interest expense $42.3M$47.6M$67.2M$69.2M$64.3M—————
Pre-tax income $257.5M$284.2M$276.0M-$93.9M$262.5M$204.1M$191.2M-$38.1M$107.1M$110.8M
Income tax $67.2M$69.6M$66.7M$11.6M$57.1M$39.4M$48.9M$2.3M$232.5M$41.5M
Net income $190.3M$214.6M$209.3M-$82.3M$205.4M$164.7M$142.3M-$35.8M$339.6M$69.4M
EPS, basic 3.934.324.21-1.654.093.282.81-0.696.401.31
EPS, diluted 3.914.294.17-1.654.043.252.78-0.696.341.30
Shares, diluted (wtd. avg.) 48.7M50.1M50.2M49.9M50.8M50.6M51.1M52.1M53.5M53.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $63.9M$97.9M$46.5M$58.5M$27.2M$32.3M$94.8M$27.5M$32.5M$41.9M
Receivables $191.9M$194.3M$176.8M$167.0M$139.3M$114.7M$150.5M$148.8M$140.9M$136.7M
Inventory $159.1M$147.7M$138.7M$162.1M$120.3M$115.0M$116.0M$119.9M$118.5M$115.6M
Total current assets $431.5M$448.3M$375.0M$391.7M$293.3M$269.8M$365.7M$300.9M$303.5M$334.4M
Property, plant and equipment $121.7M$74.5M$76.5M$70.4M$71.3M$70.1M$56.0M$51.2M$52.6M$50.6M
Goodwill $581.1M$527.4M$527.7M$527.6M$579.0M$578.1M$575.2M$578.6M$620.1M$615.3M
Other intangibles $2.30B$2.30B$2.32B$2.34B$2.70B$2.48B$2.48B$2.51B$2.78B$2.90B
Total assets $3.49B$3.40B$3.32B$3.35B$3.67B$3.43B$3.51B$3.44B$3.76B$3.91B
Accounts payable $22.8M$18.9M$39.0M$62.7M$55.8M$46.0M$62.4M$56.6M$61.4M$70.2M
Total current liabilities $120.9M$106.6M$117.0M$160.7M$143.4M$122.1M$149.9M$127.0M$123.2M$162.0M
Long-term debt $994.0M$992.4M$1.13B$1.35B$1.48B$1.48B$1.73B$1.80B$1.99B$2.19B
Total liabilities $1.61B$1.57B$1.66B$1.91B$2.09B$2.07B$2.34B$2.35B$2.58B$3.09B
Retained earnings $1.75B$1.56B$1.34B$1.13B$1.21B$1.01B$844.1M$701.8M$736.3M$396.7M
Total equity $1.89B$1.83B$1.66B$1.45B$1.58B$1.36B$1.17B$1.10B$1.18B$822.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $257.6M$251.5M$248.9M$229.7M$259.9M$235.6M$217.1M$189.3M$210.1M$148.7M
Depreciation and amortisation $31.3M$30.2M$30.7M$32.6M$32.1M$30.2M$29.0M$31.8M$33.4M$25.8M
Stock-based compensation $10.8M$11.2M$14.0M$12.4M—————$8.1M
Capital expenditure $11.2M$8.2M$9.6M$7.8M$9.6M$22.2M$14.6M$10.5M$12.5M$3.0M
Investing cash flow -$136.8M-$17.5M-$20.1M-$11.6M-$256.5M-$22.2M-$16.6M$55.4M-$11.6M-$694.6M
Financing cash flow -$156.1M-$182.1M-$241.0M-$185.8M-$7.6M-$279.4M-$131.4M-$249.3M-$209.0M$561.0M
Buybacks $156.3M$51.5M$25.0M$50.0M$0$11.9M$56.7M$50.0M$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001295947-26-000021.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2016: 882.1M Gross profit, FY2016: 500.3M Net income, FY2016: 69.4M Revenue, FY2017: 1B Gross profit, FY2017: 576.5M Net income, FY2017: 339.6M Revenue, FY2018: 975.8M Gross profit, FY2018: 555.6M Net income, FY2018: -35.8M Revenue, FY2019: 963M Gross profit, FY2019: 552.2M Net income, FY2019: 142.3M Revenue, FY2020: 943.4M Gross profit, FY2020: 547.5M Net income, FY2020: 164.7M Revenue, FY2021: 1.1B Gross profit, FY2021: 620.6M Net income, FY2021: 205.4M Revenue, FY2022: 1.1B Gross profit, FY2022: 625.3M Net income, FY2022: -82.3M Revenue, FY2023: 1.1B Gross profit, FY2023: 624.4M Net income, FY2023: 209.3M Revenue, FY2024: 1.1B Gross profit, FY2024: 634.5M Net income, FY2024: 214.6M Revenue, FY2025: 1.1B Gross profit, FY2025: 595.6M Net income, FY2025: 190.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $882.1M $1.04B $975.8M $963.0M $943.4M $1.09B $1.13B $1.13B $1.14B $1.09B
Gross profit $500.3M $576.5M $555.6M $552.2M $547.5M $620.6M $625.3M $624.4M $634.5M $595.6M
Net income $69.4M $339.6M -$35.8M $142.3M $164.7M $205.4M -$82.3M $209.3M $214.6M $190.3M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • New debt or obligation Item 2.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%